Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Takeda Pharmaceutical Ltd ADR (TAK)
Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 51,298,420
  • Shares Outstanding, K 3,164,616
  • Annual Sales, $ 29,803 M
  • Annual Income, $ 2,346 M
  • 60-Month Beta 0.63
  • Price/Sales 1.71
  • Price/Cash Flow 4.49
  • Price/Book 1.08
Trade TAK with:

Options Overview Details

View History
  • Implied Volatility 18.81% ( -2.22%)
  • Historical Volatility 20.68%
  • IV Percentile 7%
  • IV Rank 22.63%
  • IV High 49.92% on 01/26/23
  • IV Low 9.71% on 08/05/22
  • Put/Call Vol Ratio 0.31
  • Today's Volume 67
  • Volume Avg (30-Day) 513
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 15,271
  • Open Int (30-Day) 14,541

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.56
  • Growth Rate Est. (year over year) +178,292.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.67 +3.45%
on 05/31/23
17.03 -4.82%
on 05/10/23
-0.90 (-5.26%)
since 05/09/23
3-Month
15.67 +3.45%
on 05/31/23
17.15 -5.48%
on 04/06/23
+0.20 (+1.25%)
since 03/09/23
52-Week
12.28 +32.00%
on 10/21/22
17.15 -5.48%
on 04/06/23
+2.68 (+19.81%)
since 06/09/22

Most Recent Stories

More News
Why Shares of Innate Pharma Jumped Thursday

The company's collaboration agreement with Sanofi could soon pay off.

SNY : 51.24 (-0.58%)
TAK : 16.21 (+0.56%)
IPHA : 3.23 (-2.71%)
Healthy Returns: This A Rated Healthcare Stock Is a Must-Watch for May

Given the pharmaceutical industry’s robust growth prospects, drug-maker Neurocrine Biosciences’ (NBIX) stock is worth watching ahead of its first-quarter earnings next week. Read on… Investors...

NBIX : 93.39 (-0.68%)
NVO : 158.05 (-0.88%)
NVS : 100.93 (+0.28%)
TAK : 16.21 (+0.56%)
Is Your Portfolio Healthy? Don't Touch This Stock With a Ten-Foot Pole!

Amidst lingering economic uncertainties, pharma contract development company Avid Bioservices (CDMO) has been flashing red flags with deteriorating financial results in the last reported quarter and bleak...

CDMO : 16.66 (-2.69%)
NVO : 158.05 (-0.88%)
NVS : 100.93 (+0.28%)
TAK : 16.21 (+0.56%)
Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) resubmission for the investigational...

TAK : 16.21 (+0.56%)
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday

The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.

AMGN : 218.76 (-0.91%)
GSK : 34.76 (+0.12%)
TAK : 16.21 (+0.56%)
ARWR : 35.32 (-1.06%)
This Supercharged Dividend King Stock Might Soon Run Out of Steam

Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.

JNJ : 160.01 (-0.16%)
PFE : 38.97 (-0.31%)
BMY : 64.80 (-0.78%)
TAK : 16.21 (+0.56%)
GILD : 78.12 (-0.36%)
VRTX : 334.11 (+0.46%)
ABBV : 138.18 (+0.39%)
ABT : 101.69 (+0.90%)
MRK : 110.71 (+0.35%)
RXDX : 198.99 (+0.01%)
1 Pharma Stock You'll Regret Not Buying Earlier

The long-term prospects of Merck (MRK) look bright due to its latest acquisitions and solid drug pipeline. Therefore, investing in this stock could help generate substantial returns in the long run. Keep...

IMGO : 36.01 (+0.03%)
JNJ : 160.01 (-0.16%)
MRK : 110.71 (+0.35%)
NVO : 158.05 (-0.88%)
RXDX : 198.99 (+0.01%)
TAK : 16.21 (+0.56%)
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children

Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) to expand the use of HYQVIA to treat primary...

TAK : 16.21 (+0.56%)
Takeda Announces New U.S. Corporate Social Responsibility (CSR) Program Partners

Takeda ( TSE:4502/NYSE:TAK ) today announced that 21 new U.S. non-profit organizations have received grants as part of the company’s $19.5 million commitment to its FY2022 Corporate Social Responsibility...

TAK : 16.21 (+0.56%)
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

TAK : 16.21 (+0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide...

See More

Key Turning Points

3rd Resistance Point 16.40
2nd Resistance Point 16.34
1st Resistance Point 16.27
Last Price 16.21
1st Support Level 16.15
2nd Support Level 16.09
3rd Support Level 16.02

See More

52-Week High 17.15
Last Price 16.21
Fibonacci 61.8% 15.29
Fibonacci 50% 14.72
Fibonacci 38.2% 14.14
52-Week Low 12.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar